ALLMedicine™ Hypersensitivity Pneumonitis Center

May 14th, 2022 - Treatment of Hypersensitivity Pneumonitis (HP).|2022|Janssen B,Epstein S,Gomez-Manjarres D,Patel DC,|

May 6th, 2022 - By evaluating S100 calcium binding protein A9 (S100A9) and Klebs von den Lungen-6 (KL-6) expression in patients with 4 common interstitial lung diseases (ILDs), we aimed to investigate whether S100A9 or KL-6 can be of any value in the differential...

Apr 24th, 2022 - Interstitial lung diseases (ILDs) include a variety of parenchymal lung diseases. The most common types of ILDs are idiopathic pulmonary fibrosis (IPF), autoimmune ILDs and hypersensitivity pneumonitis (HP). There is limited real world data on car...

Apr 19th, 2022 - Repeated exposure to antigens via inhalation is the primary cause of hypersensitivity pneumonitis, a form of interstitial pneumonia. The chronic form of hypersensitivity pneumonitis leads to progressive loss of respiratory function; lung transplan...

Apr 15th, 2022 - Rituximab Rescue in Treatment Refractory Hypersensitivity Pneumonitis.|2022|Grewal US,Pande A,|

Apr 19th, 2021 - The purpose of this summary is to provide a synopsis of evidence-based and consensus-derived guidance for clinicians to improve individual diagnostic decision-making for hypersensitivity pneumonitis (HP) and decrease diagnostic practice variabilit...

Apr 17th, 2021 - The purpose of this analysis is to provide evidence-based and consensus-derived guidance for clinicians to improve individual diagnostic decision-making for hypersensitivity pneumonitis (HP) and decrease diagnostic practice variability. Approved p...

Jul 25th, 2020 - Background: This guideline addresses the diagnosis of hypersensitivity pneumonitis (HP). It represents a collaborative effort among the American Thoracic Society, Japanese Respiratory Society, and Asociación Latinoamericana del Tórax.Methods: Syst...

Jan 27th, 2022 - The objective of this study is to administer and validate a disease-specific health related quality of life (HRQOL) survey for patients with Chronic Hypersensitivity Pneumonitis (CHP). The survey items have been developed and revised from prior qu...

Jul 2nd, 2021 - The overall aims of this study are Identify biomarkers and gene expression profiles that determine progressive fibrotic lung disease regardless of aetiology To prospectively assess biomarkers which predict progressive fibrosis in patients with fib...

May 17th, 2021 - The purpose of this study is to evaluate the potential benefits and the safety of treatment with pirfenidone compared to placebo in subjects with FHP. STUDY SUMMARY This study will include about 42 subjects at National Jewish Health. This is a "do...

Dec 19th, 2020 - Rationale The present data about the treatment of CHP are few and largely based on observational studies and expert opinion. It is suggested that pirfenidone may slow disease progression in cases of CHP as it has some anti-inflammatory in addition...

May 26th, 2020 - hypersensitivity Pneumonitis patients will be divided in two groups : non- fibrotic hypersensitivity Pneumonitis patients ( nfHP) and fibrotic hypersensitivity Pneumonitis patients ( fHP), based on HRCT findings. All patients will undergo the foll...

Apr 19th, 2022 - Poor cough-specific quality of life (QOL) was independently associated with respiratory hospitalization, death, and lung transplantation in a large population of well-characterized patients with interstitial lung disease (ILD), new research shows....

Apr 12th, 2022 - Interstitial lung diseases (ILDs) encompass a large and varied group of parenchymal lung disorders, including diseases of unknown cause, which are known as idiopathic interstitial pneumonias, as well as those associated with other diseases or envi...

Aug 24th, 2020 - Recently developed treatments for human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer, lung cancers, and gastrointestinal (GI) cancers include antibody-drug conjugates (ADCs), cyclin-dependent kinase (CDK) 4/6 inhibitors...

Jul 9th, 2020 - Patients with interstitial lung disease–associated pulmonary hypertension who were treated with inhaled treprostinil (Tyvaso) had significantly greater improvement in exercise capacity over 16 weeks, compared with patients who used a placebo inhal...

Jun 11th, 2020 - Patients with RA have an elevated risk of interstitial lung disease (ILD), but methotrexate does not accentuate that risk and may in fact be protective, new data show. These were among key findings of a pair of studies reported at the annual Europ...